# A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

> **NCT02113813** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 133 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer (NSCLC)
- Epidermal Growth Factor Receptor Mutations

## Interventions

- **DRUG:** naquotinib
- **DRUG:** midazolam

## Key facts

- **NCT ID:** NCT02113813
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-09
- **Primary completion:** 2017-07-28
- **Final completion:** 2019-02-11
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113813, "A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02113813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*